Cargando…
Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021)
BACKGROUND: The coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese rapid/living recommendat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594767/ https://www.ncbi.nlm.nih.gov/pubmed/34815889 http://dx.doi.org/10.1002/ams2.706 |
_version_ | 1784600050776670208 |
---|---|
author | Yamakawa, Kazuma Yamamoto, Ryo Terayama, Takero Hashimoto, Hideki Ishihara, Tadashi Ishimaru, Go Imura, Haruki Okano, Hiromu Narita, Chihiro Mayumi, Takuya Yasuda, Hideto Yamada, Kohei Yamada, Hiroyuki Kawasaki, Tatsuya Shime, Nobuaki Doi, Kent Egi, Moritoki Ogura, Hiroshi Aihara, Morio Kushimoto, Shigeki Nishida, Osamu |
author_facet | Yamakawa, Kazuma Yamamoto, Ryo Terayama, Takero Hashimoto, Hideki Ishihara, Tadashi Ishimaru, Go Imura, Haruki Okano, Hiromu Narita, Chihiro Mayumi, Takuya Yasuda, Hideto Yamada, Kohei Yamada, Hiroyuki Kawasaki, Tatsuya Shime, Nobuaki Doi, Kent Egi, Moritoki Ogura, Hiroshi Aihara, Morio Kushimoto, Shigeki Nishida, Osamu |
author_sort | Yamakawa, Kazuma |
collection | PubMed |
description | BACKGROUND: The coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese rapid/living recommendations on drug management for COVID‐19 using the experience of creating the J‐SSCG. METHODS: The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on September 9, 2020, and this document is the revised edition (version 4.0; released on September 9, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ2), corticosteroids (CQ4), tocilizumab (CQ5), anticoagulants (CQ7), baricitinib (CQ8), and casirivimab/imdevimab (CQ9). Two CQs (hydroxychloroquine [CQ3] and ciclesonide [CQ6]) were retrieved in this updated version. RECOMMENDATIONS: Favipiravir is not suggested for all patients with COVID‐19 (GRADE 2C). Remdesivir is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Corticosteroids are recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 1B) and for patients with severe COVID‐19 requiring mechanical ventilation/intensive care (GRADE 1A); however, their administration is not recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). Tocilizumab is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Anticoagulant administration is recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization and patients with severe COVID‐19 requiring mechanical ventilation/intensive care (good practice statement). Baricitinib is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2C). Casirivimab/imdevimab is recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). We hope that these updated clinical practice guidelines will help medical professionals involved in the care of patients with COVID‐19. |
format | Online Article Text |
id | pubmed-8594767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85947672021-11-22 Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) Yamakawa, Kazuma Yamamoto, Ryo Terayama, Takero Hashimoto, Hideki Ishihara, Tadashi Ishimaru, Go Imura, Haruki Okano, Hiromu Narita, Chihiro Mayumi, Takuya Yasuda, Hideto Yamada, Kohei Yamada, Hiroyuki Kawasaki, Tatsuya Shime, Nobuaki Doi, Kent Egi, Moritoki Ogura, Hiroshi Aihara, Morio Kushimoto, Shigeki Nishida, Osamu Acute Med Surg Guidelines BACKGROUND: The coronavirus disease 2019 (COVID‐19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J‐SSCG) 2020 Special Committee created the Japanese rapid/living recommendations on drug management for COVID‐19 using the experience of creating the J‐SSCG. METHODS: The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on September 9, 2020, and this document is the revised edition (version 4.0; released on September 9, 2021). Clinical questions (CQs) were set for the following seven drugs: favipiravir (CQ1), remdesivir (CQ2), corticosteroids (CQ4), tocilizumab (CQ5), anticoagulants (CQ7), baricitinib (CQ8), and casirivimab/imdevimab (CQ9). Two CQs (hydroxychloroquine [CQ3] and ciclesonide [CQ6]) were retrieved in this updated version. RECOMMENDATIONS: Favipiravir is not suggested for all patients with COVID‐19 (GRADE 2C). Remdesivir is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Corticosteroids are recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 1B) and for patients with severe COVID‐19 requiring mechanical ventilation/intensive care (GRADE 1A); however, their administration is not recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). Tocilizumab is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2B). Anticoagulant administration is recommended for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization and patients with severe COVID‐19 requiring mechanical ventilation/intensive care (good practice statement). Baricitinib is suggested for patients with moderate COVID‐19 requiring supplemental oxygen/hospitalization (GRADE 2C). Casirivimab/imdevimab is recommended for patients with mild COVID‐19 not requiring supplemental oxygen (GRADE 1B). We hope that these updated clinical practice guidelines will help medical professionals involved in the care of patients with COVID‐19. John Wiley and Sons Inc. 2021-11-16 /pmc/articles/PMC8594767/ /pubmed/34815889 http://dx.doi.org/10.1002/ams2.706 Text en © 2021 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Guidelines Yamakawa, Kazuma Yamamoto, Ryo Terayama, Takero Hashimoto, Hideki Ishihara, Tadashi Ishimaru, Go Imura, Haruki Okano, Hiromu Narita, Chihiro Mayumi, Takuya Yasuda, Hideto Yamada, Kohei Yamada, Hiroyuki Kawasaki, Tatsuya Shime, Nobuaki Doi, Kent Egi, Moritoki Ogura, Hiroshi Aihara, Morio Kushimoto, Shigeki Nishida, Osamu Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) |
title | Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) |
title_full | Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) |
title_fullStr | Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) |
title_full_unstemmed | Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) |
title_short | Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (September 2021) |
title_sort | japanese rapid/living recommendations on drug management for covid‐19: updated guidelines (september 2021) |
topic | Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594767/ https://www.ncbi.nlm.nih.gov/pubmed/34815889 http://dx.doi.org/10.1002/ams2.706 |
work_keys_str_mv | AT yamakawakazuma japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT yamamotoryo japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT terayamatakero japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT hashimotohideki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT ishiharatadashi japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT ishimarugo japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT imuraharuki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT okanohiromu japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT naritachihiro japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT mayumitakuya japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT yasudahideto japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT yamadakohei japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT yamadahiroyuki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT kawasakitatsuya japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT shimenobuaki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT doikent japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT egimoritoki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT ogurahiroshi japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT aiharamorio japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT kushimotoshigeki japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT nishidaosamu japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 AT japaneserapidlivingrecommendationsondrugmanagementforcovid19updatedguidelinesseptember2021 |